North America Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The North America antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 24,726.59 million by 2031, up from USD 16,434.34 million in 2023, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period.

Executive Summary and Market Analysis

The growth of the North American antibiotics and antimycotics market is primarily driven by the increasing prevalence of infectious diseases, heightened awareness regarding antimicrobial resistance, and ongoing pharmaceutical innovations. Major industry players are investing in new formulations and combination therapies to address these challenges. Additionally, robust regulatory support and advanced healthcare systems contribute to the market's expansion. Despite facing hurdles such as drug resistance and stringent approval processes, the demand for effective antimicrobial treatments remains strong, especially in hospital environments and among immunocompromised patients.

Market Segmentation Analysis

The North America antibiotics and antimycotics market can be segmented based on drug class, indication, route of administration, and distribution channel:

Drug Class: The market includes various drug classes such as penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin held the largest market share.
Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others, with skin infections leading in market share in 2023.
Route of Administration: This includes oral, topical, and other methods, with oral administration dominating the market in 2023.
Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, where hospital pharmacies accounted for the largest share in 2023.

Market Outlook

The increasing awareness of fungal infections and their serious health implications is a significant factor driving the growth of the antibiotics and antimycotics market. The Global Action Fund for Fungal Infections (GAFFI) reported in 2023 that over 300 million people globally suffer from severe fungal diseases, leading to approximately 1.5 million deaths annually, surpassing the combined fatalities from malaria and tuberculosis. This alarming trend has prompted extensive educational initiatives and improved diagnostic capabilities, enhancing awareness among healthcare providers and patients about the necessity for timely treatment.

Innovations in diagnostic methods, such as molecular testing, have facilitated the early detection of fungal pathogens, further increasing the demand for effective antifungal treatments. The Centers for Disease Control and Prevention (CDC) has initiated programs to monitor Candida auris, enhancing laboratory capabilities and outbreak management. Furthermore, GAFFI's 10-year roadmap for eliminating fungal diseases emphasizes the essential conditions for effective diagnostics. Various organizations, including the International Society for Human and Animal Mycology (ISHAM) and the European Centre for Disease Prevention and Control (ECDC), are also working to highlight the burden of fungal infections and improve prevention, diagnosis, and treatment strategies. The annual Fungal Disease Awareness Week, observed from September 16-20, aims to raise awareness about the growing prevalence of fungal diseases and the need for appropriate responses.

Country Insights

The North American antibiotics and antimycotics market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The growth in the US market is fueled by the rising incidence of fungal and bacterial infections and the demand for effective treatment options. Pneumonia, a common respiratory infection, affects approximately 1.5 million adults annually in the US, leading to significant hospital admissions and fatalities. Amoxicillin and azithromycin are among the most frequently prescribed antibiotics in outpatient settings.

Ongoing advancements in pharmaceutical research are accelerating the development of new antibiotics and antifungal agents, addressing concerns about antibiotic resistance and the need for innovative therapies. The emphasis on antimicrobial stewardship programs is promoting a more judicious approach to antibiotic prescriptions, particularly in hospital settings where hospital-acquired infections are prevalent.

Key Players

Prominent companies in the North America antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing strategies such as product launches, approvals, and collaborations to enhance their market presence and offer innovative solutions to consumers.

Product Code: BMIRE00032104

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. North America Antibiotics and Antimycotics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. North America Antibiotics and Antimycotics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Infectious Diseases
- 5.1.2 Growing Awareness About Fungal Infections
5.2 Market Restraints
- 5.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
5.3 Market Opportunities
- 5.3.1 Ongoing Funding and Research & Development Initiatives
5.4 Future Trends
- 5.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
5.5 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - North America Analysis

6.1 North America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
6.2 North America Antibiotics and Antimycotics Market Forecast Analysis

7. North America Antibiotics and Antimycotics Market Analysis - by Drug Class

7.1 Penicillin
- 7.1.1 Overview
- 7.1.2 Penicillin: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Cephalosporines
- 7.2.1 Overview
- 7.2.2 Cephalosporines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Carbapenems
- 7.3.1 Overview
- 7.3.2 Carbapenems: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Macrolides
- 7.4.1 Overview
- 7.4.2 Macrolides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Aminoglycosides
- 7.5.1 Overview
- 7.5.2 Aminoglycosides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Quinolones
- 7.6.1 Overview
- 7.6.2 Quinolones: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Sulfonamides
- 7.7.1 Overview
- 7.7.2 Sulfonamides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Tetracyclines
- 7.8.1 Overview
- 7.8.2 Tetracyclines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.9 Azoles
- 7.9.1 Overview
- 7.9.2 Azoles: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Antibiotics and Antimycotics Market Analysis - by Indication

8.1 Skin Infections
- 8.1.1 Overview
- 8.1.2 Skin Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Respiratory Infections
- 8.2.1 Overview
- 8.2.2 Respiratory Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Urinary Tract Infections (UTI)
- 8.3.1 Overview
- 8.3.2 Urinary Tract Infections (UTI): North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Septicemia
- 8.4.1 Overview
- 8.4.2 Septicemia: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Ear Infections
- 8.5.1 Overview
- 8.5.2 Ear Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Gastrointestinal Infections
- 8.6.1 Overview
- 8.6.2 Gastrointestinal Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Antibiotics and Antimycotics Market Analysis - by Route Of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Topical
- 9.2.1 Overview
- 9.2.2 Topical: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Antibiotics and Antimycotics Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

11. North America Antibiotics and Antimycotics Market - Country Analysis

11.1 North America
- 11.1.1 North America Antibiotics and Antimycotics Market Overview
- 11.1.2 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.1.2.1 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.1.2.2 United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.1.2.2.1 United States: North America Antibiotics and Antimycotics Market Share - by Drug Class
    - 11.1.2.2.2 United States: North America Antibiotics and Antimycotics Market Share - by Indication
    - 11.1.2.2.3 United States: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 11.1.2.2.4 United States: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 11.1.2.3 Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.1.2.3.1 Canada: North America Antibiotics and Antimycotics Market Share - by Drug Class
    - 11.1.2.3.2 Canada: North America Antibiotics and Antimycotics Market Share - by Indication
    - 11.1.2.3.3 Canada: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 11.1.2.3.4 Canada: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 11.1.2.4 Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 11.1.2.4.1 Mexico: North America Antibiotics and Antimycotics Market Share - by Drug Class
    - 11.1.2.4.2 Mexico: North America Antibiotics and Antimycotics Market Share - by Indication
    - 11.1.2.4.3 Mexico: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 11.1.2.4.4 Mexico: North America Antibiotics and Antimycotics Market Share - by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in Antibiotics and Antimycotics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Pfizer Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Novartis AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck & Co Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Johnson & Johnson
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Cipla Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bayer AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Astellas Pharma Inc
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms